Immune checkpoint inhibitors (ICIs), including anti-PD-1/PD-L1 and anti-CTLA-4, improve NPC treatment by reactivating CTLs and NK cells, though efficacy is limited by the immunosuppressive TME (55). Here, CD274 is linked to nasopharyngeal carcinoma.